Induction chemotherapy for locoregionally advanced head and neck cancer: Past, present, future?

Oncologist

Volumn 18, Issue 3, 2013, Pages 288-293

  Hanna, Glenn J ^a   Haddad, Robert I ^b   Lorch, Jochen H ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; HYDROXYUREA; PACLITAXEL; PLATINUM;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; HYPOPHARYNX CARCINOMA; INDUCTION CHEMOTHERAPY; LARYNX CANCER; META ANALYSIS (TOPIC); METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; WART VIRUS;

EID: 84875423140     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0286     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organpreservationinadvancedlaryngealcancer. N Engl J Med 2003;349:2091-2098.
3. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357: 1705-1715.
4. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357: 1695-1704.
5. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-955.
6. Pignon JP, le Maître A, Maillard E et al. Meta Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
7. Pointreau Y, Atean I, Fayette J et al. Induction chemotherapy in head and neck cancer: A new paradigm. Anticancer Drugs 2011;22:613-620.
8. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer 1987;60:301-311.
9. Schuller DE, Metch B, Stein DW et al. Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-1211.
10. Rooney M, Kish J, Jacobs J et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-1128.
11. Posner M. Evolving strategies for combined modality therapy for locally advanced head and neck cancer. The Oncologist 2007;12:967-974.
12. Morrison AB, Clark JR. Induction chemotherapy. In: Snow GB, Clark JR, eds. Multimodality Therapy and Head and Neck Cancer. New York: Thieme, 1992:95-112.
13. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-1690.
14. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 2000;83:1594-1598.
15. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
16. Forastiere A, Maor M, Weber R et al. Long term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol 2006;24(suppl 18):5517.
17. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899.
18. Lefebvre JL, Andry G, Chevalier D et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012;23: 2708-2714.
19. Lefebvre JL, Rolland F, Tesselaar M et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009;101:142-152.
20. Forastiere AA, Shank D, Neuberg D et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-2274.
21. Haddad R, Colevas AD, Tishler R et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana Farber Cancer Institute experience. Cancer 2003;97:412-418.
22. Haddad R, Tishler R, Wirth L et al. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2006; 132:678-681.
23. Janinis J, Papadakou M, Panagos G et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24:227-231.
24. Schrijvers D, Van Herpen C, Kerger J et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: A phase I-II feasibility study. Ann Oncol 2004; 15:638-645.
25. van Herpen CM, Mauer ME, Mesia R et al. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer 2010;103:1173-1181.
26. Liberato NL, Rognoni C, Rubrichi S et al. Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: A costutility analysis. Ann Oncol 2012;23:1825-1832.
27. Vermorken JB, Remenar E, Van Herpen C et al. Long-term results of EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head ad neck. Preliminary results of a modern integrated approach. J Clin Oncol 2011;29(suppl 15):5530.
28. Lorch JH, Goloubeva O, Haddad RI et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011;12:153-159.
29. Posner MR, Lorch JH, Goloubeva O et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann Oncol 2011;22: 1071-1077.
30. Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506.
31. Paccagnella A, Ghi MG, Loreggian L et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study. Ann Oncol 2010;21:1515-1522.
32. Hitt R, Grau JJ, Lopez-Pousa A et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/ cisplatin/5-FU followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009;27(suppl 15):6009.
33. Haddad R, Rabinowits G, Tishler R et al. The Paradigm trial: A phase III study comparing sequential therapy to concurrent chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2012;30(suppl 15):5501.
34. Cohen EE, Karrison T, Kocherginsky M et al. DeCIDE: A phase II randomized trial of docetaxel, cisplatin, 5FU induction chemotherapy in patients with N2 N3 locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2012;30(suppl 15):5500.